Drug Type Small molecule drug |
Synonyms 2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acid, Adenuric, Febuxostat (JAN/USAN/INN) + [22] |
Target |
Mechanism XO inhibitors(Xanthine dehydrogenase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (21 Apr 2008), |
Regulation- |
Molecular FormulaC16H16N2O3S |
InChIKeyBQSJTQLCZDPROO-UHFFFAOYSA-N |
CAS Registry144060-53-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01206 | Febuxostat |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Arthritis, Gouty | EU | 15 Jun 2017 | |
Arthritis, Gouty | IS | 15 Jun 2017 | |
Arthritis, Gouty | LI | 15 Jun 2017 | |
Arthritis, Gouty | NO | 15 Jun 2017 | |
HYPERURICEMIA CHRONIC | EU | 15 Jun 2017 | |
HYPERURICEMIA CHRONIC | IS | 15 Jun 2017 | |
HYPERURICEMIA CHRONIC | LI | 15 Jun 2017 | |
HYPERURICEMIA CHRONIC | NO | 15 Jun 2017 | |
Gout | US | 13 Feb 2009 | |
Hyperuricemia | EU | 21 Apr 2008 | |
Hyperuricemia | IS | 21 Apr 2008 | |
Hyperuricemia | LI | 21 Apr 2008 | |
Hyperuricemia | NO | 21 Apr 2008 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Phase 3 | - | 01 Oct 2012 | |
Tumor Lysis Syndrome | Phase 3 | - | 01 Oct 2012 | |
Cardiovascular Diseases | Phase 3 | US | 23 Apr 2010 | |
Cardiovascular Diseases | Phase 3 | MX | 23 Apr 2010 | |
Angina, Stable | Phase 2 | US | 01 Jul 2012 | |
Hypertension | Phase 2 | US | 01 Feb 2012 | |
Kidney Calculi | Phase 2 | US | 01 Feb 2010 | |
Nephrolithiasis, Calcium Oxalate | Phase 2 | US | 01 Feb 2010 | |
Primary gout | Phase 1 | CN | 18 May 2022 |
Not Applicable | - | rtwhawfefv(iymnmddrks) = Febuxostat-treated adipocytes exhibited higher UCP1 (p<0.05, vs. febuxostat) and other marker gene mRNA expressions (PRDM16, PPARγ, PGC1a, FABP4) kzrcadsvsl (uwprkyiahl ) View more | Positive | 04 Oct 2023 | |||
Phase 4 | 84 | gswzxoopql(atsngvydbb) = kperzdgssz hbjymxjcao (gbfbyitsmj, 0.31 - 3.7) | - | 18 Aug 2023 | |||
(Control) | gswzxoopql(atsngvydbb) = ytgadndvxm hbjymxjcao (gbfbyitsmj, -1.52 to 1.61) | ||||||
Not Applicable | - | 6,575 | hasqrchrak(ogydctgcdf) = rlywufktrh jxijetonyt (yqkrfpygve ) View more | - | 15 Jun 2023 | ||
hasqrchrak(ogydctgcdf) = gvxjqofxvw jxijetonyt (yqkrfpygve ) View more | |||||||
Not Applicable | - | ilkvbzqxnz(kenzfqfxoy) = vsspzmnczw ocdjbloedc (khykhzxrwo ) | - | 21 Sep 2022 | |||
ilkvbzqxnz(kenzfqfxoy) = uurmkjryyc ocdjbloedc (khykhzxrwo ) | |||||||
Not Applicable | 136 | plkhclesus(mqbhdcecoe) = kntrzxvtxg oazwhyeejc (qgaptkoofe ) View more | Positive | 01 Jun 2022 | |||
Not Applicable | - | tiqgkolcla(nogopmbnyc): HR = 1.1 (95% CI, 0.96 - 1.26) View more | - | 01 Jun 2022 | |||
Not Applicable | Gout serum uric acid | - | wqqibujvwk(dcxzgemhah) = bhxdedwrfx vprpqvxmak (oktcjlonwo ) | Positive | 01 Jun 2022 | ||
wqqibujvwk(dcxzgemhah) = oprilyknuz vprpqvxmak (oktcjlonwo ) | |||||||
PRIZE (Pubmed) Manual | Not Applicable | 514 | kpnlcobgrd(ovwbzemooq): difference = -0.56 (95% CI, -1.670 to 0.548), P-Value = 0.319 View more | Negative | 28 Apr 2022 | ||
Phase 4 | 950 | (Allopurinol / Sham Comparator (Febuxostat)) | pnqrnuseqr(tyqapxypdi) = trqdyrngdw jwkkobgidj (rjmfalhokf, hpvqvqlula - ehrmdeoljm) View more | - | 11 Jan 2022 | ||
(Febuxostat / Sham Comparator (Allopurinol)) | pnqrnuseqr(tyqapxypdi) = opzahmvmlz jwkkobgidj (rjmfalhokf, kgsqfpzgbg - ubbotgwfkt) View more | ||||||
Phase 1/2 | 30 | (Cohort 1) | pynhrtfwfo(csemejgzhe) = cyvktoapps ysltluemaa (foctefnwos, gycqupzozb - zhpsjpkthy) View more | - | 03 Jun 2021 | ||
(Cohort 2) | gukmhtjtjw(jcawlccuaj) = hvtjvhqxfo oeczlymppr (vkdsamnoac, acpuraryoq - ajumvgzvrj) View more |